Search Results for:

Senate Judiciary Committee’s Antitrust Panel Discusses and Advances Proposed Generics and Biosimilars Bill

On July 13, 2021, the Senate Judiciary Committee’s antitrust panel met to discuss biologic and biosimilar competition and its impact on drug prices.  A group of senators, led by Senator Amy Klobuchar, are sponsors of a Senate bill which aims to prohibit biological product manufacturers from compensating biosimilar and interchangeable…

Read More

Q1 2021 Earnings Roundup: Biologics and Biosimilars Update

First Quarter Earnings Graphic

Below are some highlights from first quarter 2021 earnings reports recently released by biologics and biosimilars companies: At the end of last month, Biogen reported total quarterly revenues of $2,694 million, reflecting a 24% decrease versus the prior year’s first quarter. As reported by Biogen, this decrease reflects increased competition…

Read More

Recent Adalimumab Biosimilar Updates

On February 15, 2021, Celltrion Healthcare announced that the European Commission granted marketing authorization for Yuflyma™ (CT-P17), an adalimumab biosimilar, on February 11, 2021.  Yuflyma™ was approved across all thirteen intended indications covered by the reference biologic, Humira®.  Yuflyma™ is a high concentration, low-volume and citrate-free adalimumab biosimilar, which, according…

Read More